Seed Therapeutics

Seed Therapeutics is a global research company focused on harnessing and engineering molecules that use “molecular glues” to attack protein targets.

[Seed Therapeutics @seedtx]

#ICYMI: Seed announced a research collaboration & license agreement with Lilly to continue advancing their #MolecularGlue protein degradation technology. Learn more about this news and its impact on the future of the #TargetedProteinDegradation field: https://t.co/wycqEmVnOx

[Seed Therapeutics @seedtx]

#BREAKING: Seed Therapeutics announces a #research collaboration & license agreement with Lilly to discover & develop new chemical entities that could produce therapeutic benefit through #TargetedProteinDegradation. Learn more: https://t.co/M4tkvin27S

[Seed Therapeutics @seedtx]

Seed is proud to announce that James Tonra, Chief Scientific Officer, is serving as this year's Chair of the 3rd annual #TargetedProteinDegradation Summit. We continue to be inspired by his dedication to the advancement of one of the most promising fields in medicine.

[Seed Therapeutics @seedtx]

We are pleased to name Edward Dongheng Liu as Chief Financial Officer of Seed Therapeutics! His responsibilities as CFO will further allow the company to bring #innovative medicines to patients in need where current therapies fall short. https://t.co/MDNzqGPQGD

[Seed Therapeutics @seedtx]

Did you know 70% of proteins involved in #diseases are considered “undruggable”? To overcome this challenge, we are focused on harnessing & engineering #MolecularGlue. Learn more about the launch of our #TargetedProteinDegradation platform: https://t.co/XTTIQBhmod